
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) reported its consolidated financial results for the quarter ended 30th June 2025 (Q1FY26). The company reported a marginal decline of 1% in revenue from operations, reaching ₹1,934 crores compared to ₹1,951 crores in Q1 FY25. Notably, net loss after tax reduced to ₹82 crores from ₹89 crores in the same quarter last year, reflecting an 8% year-on-year improvement.
Revenue from Operations: ₹1,934 crores in Q1FY26, down 1% YoY
EBITDA: ₹165 crores, a 26% decline from ₹224 crores in Q1FY25
EBITDA Margin: Declined to 9% from 11%
PAT (after exceptional item): ₹(82) crores, an 8% improvement YoY
As of 29th July, 2025, 2:30 PM, Piramal Pharma share price was ₹206.07.
Net-Debt to EBITDA Ratio: 2.6x
USFDA Inspection: Aurora facility (Canada) closed with zero observations
Sustainability: ESG rating of ‘61’ for FY2024 by NSE Sustainability Ratings and Analytics Limited
The company’s overall revenue experienced a slight decline due to the impact of destocking in one large CDMO (Contract Development and Manufacturing Organisation) product. Excluding this, underlying revenue saw early double-digit growth. Other income increased sharply to ₹58 crores (up 199% YoY), boosting total income to ₹1,992 crores.
Consolidated Financials Overview
Particulars | Q1FY26 (₹ Cr) | Q1FY25 (₹ Cr) | YoY Change |
Revenue from Operations | 1,934 | 1,951 | (1)% |
Other Income | 58 | 20 | 199% |
Total Income | 1,992 | 1,971 | 1% |
EBITDA | 165 | 224 | (26)% |
Finance Cost | 86 | 107 | (19)% |
Depreciation | 197 | 185 | 7% |
Exceptional Item | 21 | - | NA |
Profit Before Tax | (79) | (45) | (75)% |
Net Profit After Tax | (82) | (89) | 8% |
Contract Development and Manufacturing Organisation (CDMO)
Revenue declined to ₹997 crores from ₹1,057 crores (down 6% YoY).
Base business (excluding destocking) saw mid-teen growth.
Overseas facilities drove growth with improved profitability.
Nutrition Supplements and Generic API also contributed positively.
Successfully completed USFDA inspection at Aurora (Canada) with zero observations.
Initiated expansion at the Lexington (US) facility for sterile injectable drug products.
Complex Hospital Generics (CHG)
Revenue rose marginally to ₹637 crores from ₹631 crores (up 1% YoY).
Inhalation Anaesthesia: Sluggish due to timing of institutional orders; recovery expected in H2FY26.
Received USFDA approval for Digwal facility (India) for Sevoflurane API and finished products.
Intrathecal Therapy and Injectable Anaesthesia faced temporary shipment and supply issues.
Launched Neoatricon® in select EU markets; more launches anticipated in Q2FY26.
Piramal Consumer Healthcare (PCH)
Strong revenue growth of 15% YoY to ₹302 crores (from ₹263 crores).
Power Brands grew 18% YoY, contributing 49% of PCH sales.
E-commerce sales increased 41% YoY, now forming 23% of PCH revenue.
7 new products launched in Q1FY26.
Advertising and promotional spending accounted for 13% of PCH sales.
Piramal Pharma’s flat revenue and subdued EBITDA performance generally aligned with sector expectations for a mixed quarter. The sector continues to grapple with supply chain pressures, inflationary input costs, and regulatory scrutiny. However, the consumer healthcare division’s robust double-digit growth, as well as strategic capacity expansions in CDMO and CHG, position the company well compared to broader industry trends.
Biotech funding constraints and delayed decision-making by customers impacted early-stage development projects across the industry, a trend also reflected in Piramal Pharma’s CDMO division. Institutional order timing further influenced sector-wide hospital generic sales, also seen in Piramal’s CHG segment performance.
Nandini Piramal, Chairperson of Piramal Pharma Limited, stated, “Excluding the impact of destocking in one large on-patent commercial product, our CDMO business delivered mid-teen revenue growth during the quarter, accompanied by improvement in EBITDA margin, especially at our overseas sites. Growth in our CHG business is also expected to pick up for the remaining part of the year given the timing of some of the institutional orders. Our consumer business delivered healthy growth, in line with our expectations, driven by power brands and ecommerce sales. Withstanding the near-term challenges, we believe we are on track to achieve our FY2030 aspirations of becoming a US$2bn revenue company with 25% EBITDA margin and high-teen ROCE.”
Source: Q1 FY25-26 Quarterly Results uploaded on 28th July on BSE.
For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading